Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006362 · ClinicalTrials.gov registry record · Phase 1
PS-341 in Treating Patients With Advanced Cancer
A Phase 1 study of Lymphoma and Leukemia, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
NCT00006362: Completed Phase 1 study of Lymphoma and Leukemia, sponsored by Mayo Clinic.
NCT00006362 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by Mayo Clinic. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006362, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced cancer.
Conditions Studied
Interventions
- DRUG bortezomib
Study Locations (2)
Minnesota
- Mayo Clinic - Rochester
Wisconsin
- University of Wisconsin Comprehensive Cancer Center - Madison
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-11 |
| Est. Completion | 2003-08 |
| Phase | Phase 1 |
What the finished NCT00006362 record still lists
NCT00006362 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 5 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which bortezomib is the first listed.
NCT00006362 reports a single indexed study location in Minnesota, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00006362 about?
NCT00006362 is a clinical study titled "PS-341 in Treating Patients With Advanced Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced cancer.
What is the current status of trial NCT00006362?
This trial is currently completed. It is a Phase 1 study. The study started on 1999-11. Estimated completion is 2003-08.
What conditions does trial NCT00006362 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Unspecified Adult Solid Tumor, Protocol Specific, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition.
What interventions are being tested in trial NCT00006362?
The interventions under investigation include: bortezomib (DRUG).
Who is sponsoring clinical trial NCT00006362?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00006362 being conducted?
This trial has 2 study locations across Minnesota, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia